|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||27.93 - 28.28|
|52 Week Range||27.48 - 34.67|
|PE Ratio (TTM)||21.34|
|Forward Dividend & Yield||1.08 (3.90%)|
|1y Target Est||N/A|
Yahoo Finance editor-in-chief Andy Serwer, Jen Rogers, Julia La Roche and Myles Udland host the halftime break show at Berkshire Hathaway's annual shareholder meeting in Omaha, Nebraska featuring Warren Buffett and Charlie Munger.
Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.
Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.
On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.
Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday. The Phase III study involved 800 people with non-squamous non-small cell lung cancer (NSCLC) whose cancer had spread but who had not yet received chemotherapy.
The study, funded by the U.K. National Institute for Health Research, was conducted on more than 4,000 women in the early stages of an aggressive type of breast cancer known as HER2-positive. Herceptin, which generated about $7 billion in global sales for Roche last year, has vastly improved treatment for HER2-positive breast cancer since it hit the market in 1998, particularly when used to prevent disease recurrence after breast surgery. In the U.S., the drug costs $76,700 for 12 months of treatment.
For more than a decade, women with a dangerous form of breast cancer have relied on Roche Holding AG’s blockbuster drug Herceptin, taking the $76,700-a-year medicine for 12 months to fight off the disease. According to research released Wednesday, women taking Herceptin for six months were just as likely to be free of cancer four years later as those who used the drug for a year, the current standard of care recommended by the U.S. Food and Drug Administration and Roche. “Our field is maturing,” said Bruce Johnson, chief clinical research officer at the Dana-Farber Cancer Institute in Boston and president of the American Society of Clinical Oncology, or ASCO.
Treating early stage breast cancer patients for just six months with Roche's Herceptin works as well as the current 12-month regimen, researchers who conducted a large clinical trial said on Wednesday. Herceptin, a biotech medicine that costs around $76,700 a year in the United States, generated 2017 worldwide sales of more than $7 billion for Roche. If a shorter treatment duration is widely adopted it could significantly reduce sales.
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.
On April 15, Merck (MRK) in collaboration with the European Organisation for Research and Treatment of Cancer (or EORTC) announced positive results from the Phase 3 KEYNOTE-054 trial, which highlighted the efficacy of Keytruda as adjuvant therapy for high-risk stage III melanoma patients who have previously undergone surgery.
Lilly signs deal to buy immuno-oncology biotech ARMO Biosciences for about $1.6 billion. J&J's Darzalex gains FDA approval in first-line setting.
Merck’s (MRK) Keytruda has managed to secure U.S. Food and Drug Administration (or FDA) approval in ten different indications across seven tumor types: melanoma, urothelial cancer, classical Hodgkin lymphoma, squamous cell carcinoma of head and neck, non-small cell lung cancer (or NSCLC), gastric cancer, and solid tumors that have microsatellite instability (or MSI) or DNA mismatch repair deficiency. The drug has already emerged as the leading immunotherapy in metastatic NSCLC, bladder cancer, and head and neck cancer indications.
In 1Q18, Merck’s (MRK) Keytruda reported global sales close to $1.5 billion, which is a year-over-year (or YoY) rise of around 151%. The rise was attributable to the highest number of new patient starts for Keytruda in the US as compared to other immunotherapy drugs such as Bristol-Myers Squibb’s (BMY) Opdivo and Roche Holdings’ (RHHBY) Tecentriq. The drug has established itself as a leading therapy for metastatic lung cancer in the US.
Exelixis stock tanked Thursday after a regimen using its drug and another from Roche failed in a late-stage study of hard-to-treat colon cancer patients.
In 1Q18, Eylea generated net global revenue of $1.6 billion compared to $1.3 billion in 1Q17, which reflected a ~20% rise on a YoY (year-over-year) basis.
Epizyme (EPZM) betters loss estimates in Q1 and expects to file a new drug application to the FDA for its lead pipeline candidate tazemetostat in fourth-quarter 2018.
Prothena's (PRTA) wider-than-expected loss in the first quarter was disappointing. Sales also missed estimates by a huge margin.
On April 30, the FDA granted priority review status to the sBLA (supplemental biologics license application) seeking approval for the combination of Merck’s (MRK) Keytruda, Eli Lilly’s (LLY) Alimta, and platinum-based chemotherapy agents like carboplatin or cisplatin in first-line metastatic NSCLC (non-squamous non-small cell lung cancer) indication. The Prescription Drug User Fee Act’s date is September 23. The sBLA is based on data from the Phase 3 KEYNOTE-189 trial declared on April 16. ...
In 1Q18, Amgen’s (AMGN) Enbrel revenue fell 6% YoY (year-over-year) to $1.1 billion from $1.2 billion, primarily due to lower unit demand and selling prices. It grew ~22% QoQ (quarter-over-quarter). In US and international markets, Enbrel generated revenue of $1.05 billion and $55 million, respectively, compared with $1.1 billion and $63 million in 1Q17.
Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday. Roche expects a U.S. Food and Drug Administration decision by Sept. 5. It has already announced some results of clinical trials that showed the cocktail boosted survival benefit for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) compared to older treatments.